DOP41 Efficacy and safety of open-label treatment with...

DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies

Chiorean, M, Su, C, Matsuoka, K, Orlando, A, Thorpe, A J, Nduaka, C I, Chapman, D S, Woodworth, D A, Lawendy, N, Friedman, G S, Cohen, R D
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
13
Journal:
Journal of Crohn's and Colitis
DOI:
10.1093/ecco-jcc/jjy222.075
Date:
January, 2019
File:
PDF, 231 KB
2019
Conversion to is in progress
Conversion to is failed